Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 12, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration ( FDA ) has
View HTML
Toggle Summary Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.
View HTML
Toggle Summary Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 5, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K.
View HTML
Toggle Summary Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Results showed significant improvement in red blood cell transfusion independence compared to placebo Safety profile generally consistent with previously published data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass.
View HTML
Toggle Summary Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from
View HTML
Toggle Summary Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
- Clinically meaningful increases in hemoglobin and reductions in red blood cell transfusion burden observed through 36 months – - Top-line results from the BELIEVE Phase 3 trial are on track for the middle of 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2018-- Acceleron Pharma Inc.
View HTML
Toggle Summary Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
– Multiple patients continue on treatment with clinically meaningful increases in hemoglobin and reduction in red blood cell transfusions surpassing 3 years – – Top-line results from the MEDALIST Phase 3 trial are on track for the middle of 2018 – – COMMANDS Phase 3 trial in first-line, lower-risk
View HTML
Toggle Summary Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
PULSAR trial expands Acceleron’s pipeline into pulmonary disease CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced
View HTML
Toggle Summary Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23 rd
View HTML
Toggle Summary Acceleron Reports First Quarter 2018 Operating and Financial Results
– Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept expected in mid-2018 – – ACE-083 advances into Part 2 of the ongoing Phase 2 trial in facioscapulohumeral muscular dystrophy – – PULSAR Phase 2 trial with sotatercept in pulmonary arterial hypertension on track to
View HTML